Preventing Hip (Proximal Femoral) Fractures: An Evidence-Based Review for Clinicians
Open Access
- 7 August 2026
- journal article
- review article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (16) , 6148
Abstract
Hip fractures are among the most devastating fragility fractures, associated with excess mortality, disability, loss of independence, and substantial healthcare costs. Although age-standardized incidence has declined in several high-income countries, absolute case numbers continue to rise because of population aging. This review summarizes contemporary PubMed-indexed evidence on the epidemiology, risk stratification, and prevention of proximal femoral fractures, with emphasis on hip-fracture outcomes rather than vertebral or composite endpoints alone. We discuss secular trends, FRAX-based case findings and screening, non-pharmacologic strategies, pharmacologic therapy, and health-system interventions relevant to both primary and secondary prevention. Among non-pharmacologic measures, long-term balance-challenging and resistance-based exercise has the most consistent evidence for reducing falls and likely contributes to fracture prevention, whereas multifactorial interventions, home hazard modification, calcium/vitamin D supplementation, and hip protectors are best targeted to selected high-risk populations and care settings. Among medications, bisphosphonates, denosumab, and romosozumab-based sequential strategies show the strongest evidence for reducing hip-fracture risk, while teriparatide and abaloparatide have important roles in very-high-risk patients despite less direct hip-fracture evidence. Menopausal hormone therapy reduces hip fractures in younger postmenopausal women but is limited by extra-skeletal risk, and selective estrogen receptor modulators are primarily vertebral-fracture agents. A major message of this review is that effective prevention depends not only on drug efficacy but also on implementation. Fracture liaison services, orthogeriatric co-management, prompt treatment after fragility fracture, and sustained adherence support are essential to close persistent care gaps. Preventing hip fractures therefore requires an integrated, risk-stratified approach that combines skeletal protection, falls prevention, and reliable health-system delivery.Keywords
This publication has 216 references indexed in Scilit:
- Interventions to Prevent Falls in Community-Dwelling Older AdultsJAMA, 2024
- Interventions to Prevent Falls in Older AdultsJAMA, 2024
- Risk Assessment and Prevention of Falls in Older Community-Dwelling AdultsJAMA, 2024
- Effect of a Home-Based Exercise Program on Subsequent Falls Among Community-Dwelling High-Risk Older Adults After a FallJAMA, 2019
- Vitamin D, Calcium, or Combined Supplementation for the Primary Prevention of Fractures in Community-Dwelling AdultsJAMA, 2018
- Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal WomenJAMA, 2017
- Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With OsteoporosisJAMA, 2016
- Health Outcomes After Stopping Conjugated Equine Estrogens Among Postmenopausal Women With Prior HysterectomyJAMA, 2011
- Annual High-Dose Oral Vitamin D and Falls and Fractures in Older WomenJAMA, 2010
- Effect of Alendronate on Risk of Fracture in Women With Low Bone Density but Without Vertebral FracturesResults From the Fracture Intervention TrialJAMA, 1998